You are here

AstraZeneca shares plunge as the firm's lung cancer study fails

Friday, July 28, 2017 - 05:50


ASTRAZENECA'S combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.

The so-called Mystic study was the most anticipated clinical experiment in the

Market voices on:

Pair your daily business read with the perfect cup of espresso.

Subscribe to The Business Times today to receive your very own Nespresso Inissia coffee machine worth $188.

Find out more at

Powered by GET.comGetCom